GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) initiated or orders passed
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts less than Nifty Midcap 150 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GlaxoSmithKline Pharmaceuticals has received a final assessment order from the Centralized Processing Centre (CPC) of the Income Tax Department raising a demand of Rs 23.21 Crores for Assessment Year 2023-24. The demand arose after the scrutiny assessment was completed. The company has stated that it is contesting this order and will be filing an appeal before the appellate authority. Importantly, management has clarified that there is currently no impact on the financial statements of the company. The disclosure has been made under SEBI Listing Regulations to keep the exchanges informed.
While the Rs 23.21 Crore tax demand is notable, the company is actively contesting it through an appeal, and management sees no immediate impact on financials. Shareholders should watch for the appeal outcome, as an unfavorable ruling could require the company to pay the demanded amount along with interest and penalties.